News

The goal was met today with a new investment of $60 million from US AARP, the global nonpartisan organisation dedicated to empowering Americans 50 and older to choose

The two forms of epilepsy that are covered by the approval are Lennox-Gastaut syndrome and Dravet syndrome in patients, aged two years or more. Epidiolex is now the

The company also announced that it plans to cease its development program for eryaspase in acute lymphoblastic leukemia (ALL), including the withdrawal of its previously submitted MAA for

The collaboration with WuXi Biologics will support the supply of Harbour's products for clinical trials under Investigational New Drug (IND) applications in China and worldwide. Harbour BioMed CEO

SNG001 was shown to be well tolerated in the two-part mid-stage trial, dubbed SG015, as per the interim safety data, said the UK-based respiratory drug discovery and development

The new facility will help the company to incorporate biologicals analytical and process development, as well as manufacturing units into one unit, enabling to maximize synergies and increase

Persistent GERD affects an estimated 10 million Americans who continue to suffer from heartburn and regurgitation despite receiving treatment with proton pump inhibitors (PPIs), the current standard of

AdoRx was founded in 2017 by leading healthcare investor Epidarex Capital and has assembled a group of highly experienced pharma industry veterans led by Pete Finan, former head

Since October 2008, the C1-Esterase inhibitor (C1-INH) has been approved in the US for routine prophylaxis against angioedema attacks in adolescents and adults with HAE. Cinryze’s latest approval